10月15日，Tempus AI盘中下跌6.3%，报66.42美元/股，成交额5016.66万美元。
消息面上，公司此前宣布扩展与Moderna及Merck的多年合作，以支持个体化癌症疗法intismeran autogene的潜在商业化，但未披露财务条款，利好对股价提振有限；相较之下，CEO兼董事长Eric Lefkofsky近期连续披露减持与拟减持安排，更直接压制市场情绪。
已披露信息显示，Eric Lefkofsky于9月22日减持726406股，9月17日减持199000股，且此前还申报拟出售20万股及25万股。叠加生命科学工具和服务板块走弱，10x Genomics跌5.5%、Illumina跌3.44%，Tempus AI短线承压明显。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.